Is Oxygenta Pharmaceutical Ltd (524636) a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Oxygenta Pharmaceutical Ltd is a below average quality company .

Is Oxygenta Pharmaceutical Ltd (524636) undervalued or overvalued?

The key valuation ratios of Oxygenta Pharmaceutical Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone .

What is Oxygenta Pharmaceutical Ltd (524636) share price return in the past 10 years?

Oxygenta Pharmaceutical Ltd share price has appreciated 17.9% annually (CAGR) over the past ten years.

Is Oxygenta Pharmaceutical Ltd (524636) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Oxygenta Pharmaceutical Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Oxygenta Pharmaceutical Ltd (524636)?

Company share prices are keep on changing according to the market conditions. The current trading price of Oxygenta Pharmaceutical Ltd (524636) on 17-Apr-2026 16:59:59 at 16:59 is 56.98.

What is the P/E ratio of Oxygenta Pharmaceutical?

The latest standalone P/E ratio of Oxygenta Pharmaceutical as of 17-Apr-2026 is 0.00.

What is the P/B ratio of Oxygenta Pharmaceutical Ltd (524636)?

The latest standalone P/B ratio of Oxygenta Pharmaceutical Ltd (524636) as of 17-Apr-2026 is -5.15.

What is the 52-week high and low of Oxygenta Pharmaceutical Ltd (524636)?

The 52-week high of Oxygenta Pharmaceutical Ltd (524636) is Rs. 133.50 and the 52-week low is Rs. 45.30.

Oxygenta Pharmaceutical Ltd (524636) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Oxygenta Pharmaceutical Ltd (524636)
Brand: Oxygenta Pharmaceutical

Oxygenta Pharmaceutical Ltd (524636) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Oxygenta Pharmaceutical Ltd (524636)

BSE: 524636 NSE:

Key Metrics

Market Cap

₹211 Cr.

P/E Ratio

0.00

Price to Book (P/B)

-5.15

Price to Sales (P/S)

1.87

EV/EBITDA

-16.61

Return on Capital Employed (ROCE)

-25.62%

Current Price

₹57

Return on Equity (ROE)

0.00%

Return on Assets (ROA)

-15.24%

Operating Profit Margin

-8.8%

Net Profit Margin

-8.86%

Gross Profit Margin

-9.6%

Book Value per Share

₹-11.1

Sales Growth (YoY)

175.73%

Sales Growth (3 Years)

21.78%

Operating Profit Growth (1 Year)

NA%

Operating Profit Growth (3 Years)

NAN%

Net Profit Growth (1 Year)

NA%

52-Week Low / High

₹45 / 134

Net Profit Growth (3 Years)

N/A%

Dividend Yield

0.00%

Promoter Holding

56.54%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Oxygenta Pharmaceutical Ltd?

Oxygenta Pharmaceutical Ltd revenue growth is 175.7% for FY-2025 , which is above its 5 year CAGR of 51.4% , indicating faster growth.

Q.1 Promoter shareholding and pledge status of Oxygenta Pharmaceutical Ltd?

Promoters hold 56.54% of the Oxygenta Pharmaceutical Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Oxygenta Pharmaceutical Ltd vs industry peers?

Oxygenta Pharmaceutical Ltd revenue CAGR is 51.44% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.

Q.1 Which industry/sub-sector does Oxygenta Pharmaceutical Ltd belong to?

Oxygenta Pharmaceutical Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Oxygenta Pharmaceutical Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 17.9% based on the current price.

DeciZen - make an informed investing decision on Oxygenta Pharma

Based on:

Data

Overall Rating ⓘ
Login to view analysis. M-Cap below 500cr. High Risk from low Liquidity

1. Quality

2. Valuation ⓘ

3. Price Trend

Oxygenta Pharmaceutical stock performance

Key Ratios

Is Oxygenta Pharmaceutical Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	0%	0%	0%	0%	0%	0%	3.2%	-50.3%	-41.7%	-25.6%	-
Value Creation Index ⓘ	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	12.4	8.2	12.9	20.5	13.7	52	60.5	31	39.6	109	113
Sales YoY Gr.	-	-34.4%	57.9%	59.4%	-33.1%	279.2%	16.3%	-48.8%	27.9%	175.7%	-
Adj EPS ⓘ	-5.4	-5.7	-4.4	-3.2	-8.4	2.9	-0	-7.8	-1.1	-2.6	-4.9
YoY Gr.	-	NA	NA	NA	NA	NA	-101.1%	NA	NA	NA	-
BVPS (₹) ⓘ	-21.1	-26.8	-31.3	-34.5	-40.1	-37.3	-24.4	-32.5	-6.2	-6.8	-11.1
Adj Net Profit ⓘ	-5.5	-5.8	-4.5	-3.3	-8.6	2.9	-0	-11.1	-3.5	-9.4	-18
Cash Flow from Ops. ⓘ	0.9	0.5	1.3	-7.8	-2.6	-1.6	-1.7	-1.6	-13.1	2.6	-
Debt/CF from Ops. ⓘ	20.6	37	14.9	-2.9	-10.4	-29.5	-31	-41.6	-4.4	23.9	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	27.3%	51.4%	21.8%	175.7%
Adj EPS ⓘ	NA	NA	NA	NA
BVPSⓘ	NA	NA	NA	NA
Share Price	17.9%	50.8%	22%	-27.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	29.2	23.7	15.3	9.7	22.5	-7.4	0.1	27.4	10.6	41.7	54.7
Op. Profit Mgn % ⓘ	-33.5	-59.4	-31.1	-10	-57.4	7.4	2.4	-23	-24.4	-8.8	-15.3
Net Profit Mgn % ⓘ	-44.3	-71.2	-35.2	-15.9	-62.5	5.6	-0.1	-35.7	-8.9	-8.6	-16
Debt to Equity ⓘ	-0.8	-0.7	-0.6	-0.6	-0.7	-1.3	-1.5	-1.5	-2.8	-2.5	-
Working Cap Days ⓘ	194	290	151	122	216	82	82	217	235	96	96
Cash Conv. Cycle ⓘ	-247	-229	-154	-75	-14	-11	-0	52	26	-2	-140

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	-4.9	-
TTM Sales (₹ Cr.)	113	-
BVPS (₹) ⓘ	-11.1	-
Reserves (₹ Cr.) ⓘ	-78	-
P/BV ⓘ	-5.15	-
PE ⓘ	0.00	-

From the Market
52 Week Low / High (₹)	45.30 / 133.50
All Time Low / High (₹)	0.10 / 133.50
Market Cap (₹ Cr.)	211
Equity (₹ Cr.)	37
Face Value (₹)	10
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Oxygenta Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	12	8	13	21	14	52	61	31	40	109
Operating Expenses ⓘ +	17	13	17	23	22	48	59	38	49	119
Manufacturing Costs	3	3	3	2	2	6	9	7	7	12
Material Costs	8	6	10	16	16	37	47	24	34	96
Employee Cost	3	3	3	3	2	4	1	6	6	7
Other Costs ⓘ	2	2	1	1	1	2	2	2	2	3
Operating Profit ⓘ	-4	-5	-4	-2	-8	4	1	-7	-10	-10
Operating Profit Margin (%)	-33.5%	-59.4%	-31.1%	-10.0%	-57.4%	7.4%	2.4%	-23.0%	-24.5%	-8.9%
Other Income ⓘ +	0	1	1	0	0	0	0	0	0	1
Exceptional Items ⓘ	0	0	0	0	4	2	1	-1	0	-0
Interest ⓘ	1	1	1	1	1	2	1	1	2	2
Depreciation ⓘ	1	1	1	1	1	1	2	2	3	1
Profit Before Tax ⓘ	-6	-6	-4	-3	-6	3	-0	-11	-14	-12
Tax ⓘ	-0	0	0	-0	-0	0	0	0	-10	-2
Profit After Tax	-5	-6	-5	-3	-6	3	-1	-12	-3	-10
PAT Margin (%)	-44.3%	-71.2%	-35.2%	-15.9%	-42.2%	5.6%	-1.0%	-37.3%	-8.8%	-8.9%
Adjusted EPS (₹)	-5.4	-5.7	-4.4	-3.2	-5.7	2.9	-0.4	-8.2	-1.0	-2.6
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	-22	-27	-32	-35	-41	-38	-35	-46	-21	-25
Share Capital ⓘ	10	10	10	10	10	10	14	14	33	37
Reserves ⓘ	-32	-38	-42	-45	-51	-48	-49	-60	-54	-62
Debt +	17	18	18	21	26	48	52	67	56	61
Long Term Debt	17	18	18	21	25	45	51	62	49	22
Short Term Debt	0	0	0	0	0	3	1	5	7	40
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	15	9	11	9	8	14	6	24	23	30
Others Liabilities ⓘ	10	19	20	26	26	10	7	9	-4	6
Total Liabilities ⓘ	20	19	17	21	19	34	31	54	54	73
Fixed Assets
Net Fixed Assets ⓘ +	13	12	12	12	11	16	20	28	29	40
Gross Block	23	23	24	25	25	31	36	46	51	61
Accumulated Depreciation	10	11	12	13	14	15	16	19	21	22
CWIP ⓘ	0	0	0	0	0	1	0	0	0	0
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	1	2	2	5	4	12	7	12	14	21
Trade Receivables	1	1	0	1	0	2	2	10	7	5
Cash Equivalents	0	0	0	0	0	0	0	0	0	0
Others Assets ⓘ	4	3	3	3	2	3	2	4	4	7
Total Assets ⓘ	20	19	17	21	19	34	31	54	54	73

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	1	1	1	-8	-3	-2	-2	-2	-13	3
PBT ⓘ	-6	-6	-4	-3	-6	3	-0	-11	-14	-12
Adjustment ⓘ	1	1	2	2	2	3	3	4	4	2
Changes in Working Capital ⓘ	5	5	4	-6	1	-8	-4	6	-3	12
Tax Paid ⓘ	0	-0	-0	0	0	-0	-0	0	0	-0
Cash Flow From Investing Activity ⓘ +	-2	-1	-0	-1	-0	-7	-5	-10	-4	-11
Capex	-2	-1	-0	-1	-1	-7	-5	0	-4	-11
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	-10	0	0
Cash Flow From Financing Activity ⓘ +	1	0	-1	8	3	9	6	11	17	9
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	4	0	29	5
Net Proceeds from Borrowing ⓘ	2	1	0	9	4	10	3	13	-11	-27
Interest Paid ⓘ	-1	-1	-1	-1	-1	-2	-1	-1	-2	-2
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0	0	0	-0	0	-0	0	0	1	32
Net Cash Flow ⓘ	-0	0	-0	0	0	0	-0	-0	-0	0

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ROCE (%)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover Ratio	0.66	0.42	0.71	1.08	0.69	1.98	1.86	0.73	0.73	1.72
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	-0.67	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	31	53	19	9	12	7	10	69	81	21
Inventory Days	21	63	49	61	128	57	58	112	117	57
Payable Days	584	790	368	224	200	109	78	230	254	100

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Oxygenta Pharmaceutical Ltd FAQs

The current trading price of Oxygenta Pharma on 17-Apr-2026 16:59 is ₹56.98.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Oxygenta Pharma stood at ₹210.7 Cr

The latest P/E ratio of Oxygenta Pharma as of 16-Apr-2026 is 0.00.

The latest P/B ratio of Oxygenta Pharma as of 16-Apr-2026 is -5.15.

The 52-week high of Oxygenta Pharma is ₹133.5 and the 52-week low is ₹45.30.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Oxygenta Pharma is ₹113 ( Cr.) .

About Oxygenta Pharmaceutical Ltd

SS Organics was incorporated in 1990, is a pharmaceutical company involved in the manufacture and marketing of bulk drugs and intermediates.

A wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs are manufactured. The product range also includes omeprazole, rabeprazole sodium, lansoprazole, esomeprazole magnesium trihydrate, non-pariel seeds, pantoprazole pellets, diclofenac sodium pellets, gabapentior, mooxafloxacin, ramipril, atorvastatin, and voriconazole.

Designed and built as per US FDA standards for production of bulk drugs and custom synthesis of intermediates, the plant located in the Medak district of Andhra Pradesh has an installed capacity 320 TPA. Major export destinations include Europe, USA, South America, and Asia Pacific Region. It reaches the America markets through its subsidiary based in Maryland, USA.

The registered office is at Survey No 252/1, Aroor Village, Sadasivapet Mandal, Medak, Andhra Pradesh.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Oxygenta Pharmaceutical Ltd (524636) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Oxygenta Pharma Share Price